Human molecular genetics · 2014
Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vacic Vladimir, Ozelius Laurie J, Clark Lorraine N, Bar-Shira Anat, Gana-Weisz Mali, Gurevich Tanya, Gusev Alexander, Kedmi Merav, Kenny Eimear E, Liu Xinmin, Mejia-Santana Helen, Mirelman Anat, Raymond Deborah, Saunders-Pullman Rachel, Desnick Robert J, Atzmon Gil, Burns Edward R, Ostrer Harry, Hakonarson Hakon, Bergman Aviv, Barzilai Nir, Darvasi Ariel, Peter Inga, Guha Saurav, Lencz Todd, Giladi Nir, Marder Karen, Pe'er Itsik, Bressman Susan B, Orr-Urtreger Avi
Аннотация
The recent series of large genome-wide association studies in European and Japanese cohorts established that Parkinson disease (PD) has a substantial genetic component. To further investigate the genetic landscape of PD, we performed a genome-wide scan in the largest to date Ashkenazi Jewish cohort of 1130 Parkinson patients and 2611 pooled controls. Motivated by the reduced disease allele heterogeneity and a high degree of identical-by-descent (IBD) haplotype sharing in this founder population, we conducted a haplotype association study based on mapping of shared IBD segments. We observed significant haplotype association signals at three previously implicated Parkinson loci: LRRK2 (OR = 12.05, P = 1.23 × 10(-56)), MAPT (OR = 0.62, P = 1.78 × 10(-11)) and GBA (multiple distinct haplotypes, OR > 8.28, P = 1.13 × 10(-11) and OR = 2.50, P = 1.22 × 10(-9)). In addition, we identified a novel association signal on chr2q14.3 coming from a rare haplotype (OR = 22.58, P = 1.21 × 10(-10)) and replicated it in a secondary cohort of 306 Ashkenazi PD cases and 2583 controls. Our results highlight the power of our haplotype association method, particularly useful in studies of founder populations, and reaffirm the benefits of studying complex diseases in Ashkenazi Jewish cohorts.